Harbour BioMed successfully doses antiCTLA-4 antibody

By The Science Advisory Board staff writers

January 25, 2022 -- Harbour BioMed has successfully completed dosing of the first patient in a phase IB/IIA trial at the stage of dose expansion of its anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, HBM4003, in combination therapy with toripalimab, an antiprogrammed cell death protein 1 (PD-1) antibody, for patients suffering from advanced melanoma and solid tumors.

The antibody showed a good safety profile and strong efficacy in the monotherapy study of the phase I trial, according to the company. Harbour BioMed is seeking to conduct studies of HBM4003 in combination therapy as a treatment for multiple solid tumors, including melanoma, non-small cell lung cancer, hepatocellular carcinoma, neuroendocrine tumors, and neuroendocrine carcinoma.

HBM4003 is a fully human antiCTLA-4 monoclonal heavy chain-only antibody generated from Harbour mice. By enhancing antibody-dependent cell cytotoxicity-killing activity, the antibody can improve depletion specific to high CTLA-4 Treg cells in tumor tissues, the firm said.

Harbour BioMed is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics that are focused on immunology and oncology.

Harbour BioMed, Hualan Genetic partner on antibody programs
Harbour BioMed and Hualan Genetic Engineering have entered a strategic partnership agreement to develop three proprietary monoclonal and bispecific antibodies...
Harbour BioMed, Vir to develop new therapies
Harbour Biomed and Vir Biotechnology have partnered to research and develop novel immuno-oncology and infectious disease therapies.

Copyright © 2022 scienceboard.net

International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
American Society of Cell & Gene Therapy Annual Meeting
May 16-19
Washington, District of Columbia United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter